Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies
- PMID: 40475129
- PMCID: PMC12138944
- DOI: 10.1016/j.ajoc.2025.102345
Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies
Abstract
Purpose: To report two new cases and summarize one case of uveal melanoma following treatment of hematologic malignancies with Bruton's tyrosine kinase inhibitors.
Observations: A 71-year-old male, with a history of Waldenstrom macroglobulinemia treated with an anti-CD20 antibody and BTKi, was diagnosed with a choroidal melanoma with intraocular metastasis. A 73-year-old female, with a history of Mantle Cell Lymphoma treated with an alkylating chemotherapy and an anti-CD20 antibody, relapse, and subsequent treatment with BTKi, was diagnosed with a uveal melanoma.
Conclusions and importance: Patients being treated with BTK inhibitors may be at higher risk for the development of uveal melanoma. Based on our findings, we recommend increased surveillance of this patient population for secondary primary or metastatic uveal melanoma. Continued documentation of occurrence in conjunction with research at a molecular and cellular level are warranted to better understand the impact of systemic cancer therapies on secondary malignancies.
Keywords: Bruton's tyrosine kinase inhibitor; Hematologic malignancy; Uveal melanoma.
© 2025 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures


Similar articles
-
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.Aging (Albany NY). 2021 Sep 10;13(17):21102-21121. doi: 10.18632/aging.203314. Epub 2021 Sep 10. Aging (Albany NY). 2021. PMID: 34508613 Free PMC article.
-
Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.J Oncol Pharm Pract. 2024 Jan;30(1):182-188. doi: 10.1177/10781552231216886. Epub 2023 Dec 3. J Oncol Pharm Pract. 2024. PMID: 38043933 Review.
-
Role of Bruton's tyrosine kinase in B cells and malignancies.Mol Cancer. 2018 Feb 19;17(1):57. doi: 10.1186/s12943-018-0779-z. Mol Cancer. 2018. PMID: 29455639 Free PMC article. Review.
-
Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.Front Immunol. 2022 Oct 17;13:1001482. doi: 10.3389/fimmu.2022.1001482. eCollection 2022. Front Immunol. 2022. PMID: 36325357 Free PMC article.
-
Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.J Hematol Oncol. 2023 Aug 25;16(1):99. doi: 10.1186/s13045-023-01496-4. J Hematol Oncol. 2023. PMID: 37626420 Free PMC article. Review.
References
-
- Metastatic uveal melanoma - UpToDate. https://www.uptodate.com/contents/metastatic-uveal-melanoma
-
- Initial management of uveal and conjunctival melanomas - UpToDate. https://www.uptodate.com/contents/initial-management-of-uveal-and-conjun...
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources